One World Products Inc
For the period ended Jun 30, 2024. Filed Aug 21, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 21, 2024
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-03-31; filed 2024-06-12.
0001493152-24-023530
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSDEFAULTS UPON SENIOR SECURITIESMINE SAFETY DISCLOSURESCurrent report: 10-Q
Period ended 2024-06-30; filed 2024-08-21.
0001493152-24-033467
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSDEFAULTS UPON SENIOR SECURITIESMINE SAFETY DISCLOSURESThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 16 previous paragraphs and 9 current paragraphs.
6 unchanged; 2 reworded; 1 added; 8 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 5 previous and 3 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (1)
Current report
On May 10, 2024, the Company issued 1,250,000 shares of common stock, restricted in accordance with Rule 144, to a consultant for services provided.
Removed paragraphs (8)
Previous report
Common Stock Issued in Escrow Pursuant to Default Provisions of Debt Financing
Previous report
On March 4, 2024, the Company issued 10,394,610 shares of common stock, restricted in accordance with Rule 144, in escrow pursuant to default provisions on deft financing received from the Sanguine Group. The shares are being cancelled pursuant to the subsequent debt repayment on April 22, 2024.
Previous report
On March 19, 2024, the Company paid a commitment fee to Joerg Sommer, the Company’s President, in the form of 250,000 shares of common stock, restricted in accordance with Rule 144, in connection with the issuance of the Second Sommer Note.
Previous report
On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., agreed to issue shares of common stock, restricted in accordance with Rule 144, to officers and directors in consideration for extending the maturity dates and terms of previously received debt financing, as listed below. The aggregate fair value of the common stock was $724,086, based on the closing price of the Company’s common stock on the date of grant, which was recognized as a loss on early extinguishment of debt. The previously issued promissory notes were cancelled in exchange for promissory notes with a maturity date of March 1, 2027, bearing interest at 10% per annum, with the exception of the promissory note issued to Dr. John McCabe, which carries an interest rate of 7% per annum.
Previous report
On June 15, 2023, the Company issued 1,500,000 shares of common stock, restricted in accordance with Rule 144, to the Company’s President, Joerg Sommer, for services provided.
Previous report
On March 15, 2024, the Company issued shares of common stock, restricted in accordance with Rule 144, to officers and directors for services provided, as listed below.
Previous report
Common Stock Issued for Services
Previous report
On March 15, 2024, the Company issued an aggregate 500,000 shares of common stock, restricted in accordance with Rule 144, to two consultants for services provided.
Reworded paragraphs (2)
Previous wording
On February 9, 2024, the Company issued 149,621 shares of common stock, restricted in accordance with Rule 144, to ClearThink Capital Partners, LLC, for services provided.
Current wording
On May 10, 2024, 2024, the Company issued 381,680 shares of common stock, restricted in accordance with Rule 144, to ClearThink Capital Partners, LLC, for services provided.
Previous wording
On March 4, 2024, the Company paid a commitment fee to The Sanguine Group, LLC in the form of 2,500,000 shares of common stock, restricted in accordance with Rule 144, in connection with the issuance of the First Sanguine Note.
Current wording
On May 10, 2024, the Company paid a commitment fee to AJB Capital in the form of 2,000,000 shares of common stock, restricted in accordance with Rule 144, in connection with the issuance of a promissory note.